What were the key takeaways from Evolent Health's earnings call?

What is Evolent Health's latest dividend and current dividend yield?

What is Evolent Health's gross profit margin?

What is the revenue and EPS growth rate for Evolent Health year over year?

What factors drove the changes in Evolent Health's revenue and profit?

What is the market's earnings forecast for Evolent Health next quarter?

What guidance did Evolent Health's management provide for the next earnings period?

What were the key takeaways from Evolent Health’s earnings call?

- **Revenue Beats Expectations**: Q3 revenue $479.5 million, full-year guidance $1.87-1.88 billion.
- **$500M New Contracts**: Blue Cross oncology deal and provider partnership add $550M 2026 revenue, $750M+ pipeline.
- **Margin Expansion**: 23% EBITDA growth to $39M; 90% of 2026 Performance Suite revenue protected.
- **Debt Reduction**: $100M debt paydown from Care Partners sale, lowering interest costs by $10M annually.
- **Oncology Growth**: Targeting 15% market share, $15B+ annual opportunity. Navigation program reduces inpatient utilization by 40%.
- **Risk Management**: 10% target margins for new contracts, conservative 2026 EBITDA outlook due to exchange uncertainty.

**【CEO Summary Section】**
- **Q3 Revenue Growth**: $479.5 million, at the top of guidance range, with full-year revenue projected between $1.87 billion and $1.88 billion.
- **New Contracts**: Signed two major deals contributing $500 million annually, including a Blue Cross plan for oncology care and a provider-sponsored health plan partnership. Total 2026 pipeline exceeds $650 million.
- **Margin Expansion**: Adjusted EBITDA of $39 million (23% YoY growth), with 90% of 2026 Performance Suite revenue protected by prevalence adjustments and risk corridors.
- **Capital Allocation**: Sale of Evolent Care Partners to reduce debt by $100 million, lowering annual interest costs by $10 million.
- **Long-Term Outlook**: Targeting 15% oncology market penetration, representing $15 billion+ annual opportunity. New contracts expected to generate $75 million+ EBITDA at maturity.

**【CFO Financial Commentary】**
- **Q3 Financials**: Revenue $480 million (8% sequential growth), adjusted EBITDA $39 million. Sequential growth driven by higher fee launches in oncology and musculoskeletal care.
- **Cash Flow**: $15 million cash from operations, offset by $40 million in debt refinancing. Year-end net debt projected at $805-$840 million.
- **Utilization Trends**: 11% oncology cost trend, stable in Medicaid/Medicare but elevated in exchanges due to pre-2026 benefit rush. Conservative reserving maintained.
- **Balance Sheet**: $116.7 million cash, $47.5 million revolver availability. No debt maturities until 2029.

**【Q&A Key Highlights】**
- **Contract Margins**: New contracts target 10% mature margins, with narrower risk corridors and value-sharing with partners.
- **2026 EBITDA Outlook**: Uncertain due to exchange membership decline (15%-65% range). Base case assumes no growth; upside if exchange subsidies extended.
- **MA Enrollment**: Potential for share gains among large customers, benefiting tech/services suite. CMS forecasts 3% MA contraction.
- **Oncology Navigation**: Reduces inpatient utilization by 40%, with 90% patient satisfaction. Rolling out to additional markets in 2026.
- **Provider Partnership**: American Oncology Network collaboration aims to eliminate utilization management, integrating Evolent's care navigation into EMRs.
- **AI Efficiency**: On track for $20 million annual savings from AI-driven authorization workflows.


EVH

EVH fundamentals

You can ask Aime